Mei-Yin Polley to Brain Neoplasms
This is a "connection" page, showing publications Mei-Yin Polley has written about Brain Neoplasms.
Connection Strength
1.920
-
Conditional probability of survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2011 Nov 01; 29(31):4175-80.
Score: 0.271
-
Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Neuro Oncol. 2010 Mar; 12(3):274-82.
Score: 0.239
-
Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. J Clin Oncol. 2022 08 10; 40(23):2539-2545.
Score: 0.142
-
Leveraging external data in the design and analysis of clinical trials in neuro-oncology. Lancet Oncol. 2021 10; 22(10):e456-e465.
Score: 0.135
-
Heparan sulfate sulfatase SULF2 regulates PDGFRa signaling and growth in human and mouse malignant glioma. J Clin Invest. 2012 Mar; 122(3):911-22.
Score: 0.069
-
Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol. 2011 Dec; 13(12):1331-8.
Score: 0.067
-
Pediatric intracranial ependymoma: the roles of surgery, radiation and chemotherapy. J Neurooncol. 2012 Jan; 106(2):367-75.
Score: 0.067
-
An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011 Jul; 115(1):3-8.
Score: 0.065
-
Identifying the needs of brain tumor patients and their caregivers. J Neurooncol. 2011 Sep; 104(3):737-44.
Score: 0.065
-
Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol. 2011 Apr; 13(4):384-92.
Score: 0.065
-
Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme. Neuro Oncol. 2011 May; 13(5):546-57.
Score: 0.065
-
Impact of bevacizumab chemotherapy on craniotomy wound healing. J Neurosurg. 2011 Jun; 114(6):1609-16.
Score: 0.064
-
Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. Neuro Oncol. 2011 Jan; 13(1):119-31.
Score: 0.063
-
Assessment of morbidity following resection of cingulate gyrus gliomas. Clinical article. J Neurosurg. 2011 Mar; 114(3):640-7.
Score: 0.063
-
Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM. Neuro Oncol. 2010 Nov; 12(11):1152-61.
Score: 0.062
-
Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. Clinical article. J Neurosurg. 2011 Mar; 114(3):566-73.
Score: 0.062
-
Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme. Neuro Oncol. 2010 Sep; 12(9):908-16.
Score: 0.062
-
Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. Neuro Oncol. 2010 Jun; 12(6):608-13.
Score: 0.060
-
Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res. 2010 Jan 15; 70(2):512-9.
Score: 0.060
-
Insular glioma resection: assessment of patient morbidity, survival, and tumor progression. J Neurosurg. 2010 Jan; 112(1):1-9.
Score: 0.060
-
Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. J Neurooncol. 2010 Mar; 97(1):33-40.
Score: 0.058
-
Quality of life in low-grade glioma patients receiving temozolomide. Neuro Oncol. 2009 Feb; 11(1):59-68.
Score: 0.054